Announcement on Voluntary Disclosure of the First Subject Being Enrolled in Phase II Clinical Trial of Pegylated Irinotecan in Treating Triple Negative Breast Cancer with Brain Metastasis

About this update from Jenkem Technology Co., Ltd. Class A

Announcement on Voluntary Disclosure of the First Subject Being Enrolled in Phase II Clinical Trial of Pegylated Irinotecan in Treating Triple Negative Breast Cancer with Brain Metastasis The abstract is for reference only. Please refer to the full text of the announcement on the very day. Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Jenkem Technology Co., Ltd. Class A